Serine/threonine kinase Mirk/Dyrk1B mediates survival in rhabdomyosarcomas

被引：0
|
作者：
Shah, SS [1 ]
Mercer, SE [1 ]
Ewton, DZ [1 ]
Naqvi, A [1 ]
Friedman, E [1 ]
机构：
[1] SUNY, Upstate Med Univ, Syracuse, NY USA
来源：
MODERN PATHOLOGY | 2006年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
71
引用
收藏
页码：18A / 18A
页数：1
相关论文
共 50 条
  • [31] Implication of DYRK1B Kinase in ovarian cancers and utilization of DYRK1B Inhibitors as a novel therapeutic strategy for ovarian cancer
    Kuznetsova, Alexandra
    Damiani, Arianna
    De Leon, Lita
    Frid, Michael
    Duey, Menelik
    Law, Jason
    Potapova, Olga
    Vilenchik, Maria
    CANCER RESEARCH, 2019, 79 (13)
  • [32] Ovarian Cancer Cells, not Normal Cells, Are Damaged by Mirk/Dyrk1B Kinase Inhibition (vol 132, pg 2258, 2013)
    Hu, J.
    Deng, H.
    Friedman, E. A.
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (06) : E13 - E13
  • [33] Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma.
    Vilenchik, Maria
    Kuznetsova, Alexandra
    Frid, Michael
    Duey, Menelik
    Damiani, Arianna
    De Leon, Lita
    Law, Jason
    Golbin, Denis A.
    Shishkina, Ludmila V.
    Potapova, Olga
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Mirk/Dyrk1B mediates cell survival and G0/G1 phase of cell cycle via interacting with MAPK/ERK pathway in human cancer cells
    Gao, Jingchun
    CANCER RESEARCH, 2012, 72
  • [35] Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome
    Ashford, Anne L.
    Dunkley, Tom P. J.
    Cockerill, Mark
    Rowlinson, Rachel A.
    Baak, Lisa M.
    Gallo, Raffaella
    Balmanno, Kathryn
    Goodwin, Louise M.
    Ward, Richard A.
    Lochhead, Pamela A.
    Guichard, Sylvie
    Hudson, Kevin
    Cook, Simon J.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2016, 73 (04) : 883 - 900
  • [36] Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome
    Anne L. Ashford
    Tom P. J. Dunkley
    Mark Cockerill
    Rachel A. Rowlinson
    Lisa M. Baak
    Raffaella Gallo
    Kathryn Balmanno
    Louise M. Goodwin
    Richard A. Ward
    Pamela A. Lochhead
    Sylvie Guichard
    Kevin Hudson
    Simon J. Cook
    Cellular and Molecular Life Sciences, 2016, 73 : 883 - 900
  • [37] Mirk/dyrk1B kinase inhibition increases ROS and apoptosis in ovarian cancer cells, but has little effect on normal diploid cells
    Hu, Jing
    Friedman, Eileen A.
    CANCER RESEARCH, 2012, 72
  • [38] The Metabolic Syndrome and DYRK1B
    Morita, Hiroyuki
    Komuro, Issei
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (08): : 785 - 785
  • [39] Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells
    Gao, Jingchun
    Zhao, Yi
    Lv, Yunyi
    Chen, Yamin
    Wei, Bing
    Tian, Jianxin
    Yang, Zhihai
    Kong, Fandou
    Pang, Jian
    Liu, Jiwei
    Shi, Hong
    CANCER CELL INTERNATIONAL, 2013, 13
  • [40] Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation
    Deng, XB
    Ewton, DZ
    Mercer, SE
    Friedman, E
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (06) : 4894 - 4905
12345